125 related articles for article (PubMed ID: 34875656)
1. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
Schenck K; Masetti M; Pfarr N; Lorenzen S
Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
[TBL] [Abstract][Full Text] [Related]
2. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
3. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Rousseau B; Bieche I; Pasmant E; Hamzaoui N; Leulliot N; Michon L; de Reynies A; Attignon V; Foote MB; Masliah-Planchon J; Svrcek M; Cohen R; Simmet V; Augereau P; Malka D; Hollebecque A; Pouessel D; Gomez-Roca C; Guimbaud R; Bruyas A; Guillet M; Grob JJ; Duluc M; Cousin S; de la Fouchardiere C; Flechon A; Rolland F; Hiret S; Saada-Bouzid E; Bouche O; Andre T; Pannier D; El Hajbi F; Oudard S; Tournigand C; Soria JC; Champiat S; Gerber DG; Stephens D; Lamendola-Essel MF; Maron SB; Diplas BH; Argiles G; Krishnan AR; Tabone-Eglinger S; Ferrari A; Segal NH; Cercek A; Hoog-Labouret N; Legrand F; Simon C; Lamrani-Ghaouti A; Diaz LA; Saintigny P; Chevret S; Marabelle A
Cancer Discov; 2022 Jun; 12(6):1435-1448. PubMed ID: 35398880
[TBL] [Abstract][Full Text] [Related]
5. POLE somatic mutations in advanced colorectal cancer.
Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
[TBL] [Abstract][Full Text] [Related]
7. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
9. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Molecular Characterization of
Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA
JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036
[TBL] [Abstract][Full Text] [Related]
12. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
13. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
14. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
16. Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer.
Voutsadakis IA
Gene; 2018 Mar; 647():31-38. PubMed ID: 29320758
[TBL] [Abstract][Full Text] [Related]
17. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
18. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
Momen S; Fassihi H; Davies HR; Nikolaou C; Degasperi A; Stefanato CM; Dias JML; Dasgupta D; Craythorne E; Sarkany R; Papa S; Nik-Zainal S
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645345
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.
Zhang L; Chen Y; Lv Y; Jiao S; Zhao W
Oncologist; 2022 Apr; 27(4):245-250. PubMed ID: 35380719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
